Australian company, Eiffel Technologies Ltd utilises supercritical fluid (SCF) technologies to re-engineer pharmaceuticals and proteins to improve their bioavailability and effectiveness.
These technologies can be used to produce uniform, nano-scale particles with a very narrow size distribution, which have the potential to be delivered in more convenient and effective dose forms, such as reengineering an intravenous drug for delivery via inhaler.
SCF technology is well placed to enable the development of line extension products with superior performance to protect market share once patent life of branded pharmaceuticals expires.
Eiffel sponsors continuing research in pharmaceutical processing at its Pharmaceutical Re-engineering Facility at the University of NSW. Eiffel has signed eleven agreements since 2000, including those with Profile Therapeutics, Sheffield Pharmaceuticals, Amarin Corp, Oriel Therapeutics, Battellepharma and Meridica.
Nano-biotechnology, Therapeutic Agents, Drug Delivery, Supercritical Fluid, Nanoparticles.